Tamoxifen and aromatase inhibitors are used to target estrogen receptor (ER) a in breast cancer patients (1). However, hormone resistance remains a clinical problem and a major cause of recurrence and mortality in ERa-positive disease (2,3). It is unlikely that simple loss of ERa signaling is the driving force for resistance because both metastatic tumors and tamoxifen-resistant breast cancer cell lines frequently retain ERa expression (4,5) and remain responsive to steroidal antiestrogens like fulvestrant.
Tamoxifen and aromatase inhibitors are used to target estrogen receptor (ER) a in breast cancer patients (1) . However, hormone resistance remains a clinical problem and a major cause of recurrence and mortality in ERa-positive disease (2, 3) . It is unlikely that simple loss of ERa signaling is the driving force for resistance because both metastatic tumors and tamoxifen-resistant breast cancer cell lines frequently retain ERa expression (4, 5) and remain responsive to steroidal antiestrogens like fulvestrant.
Several mechanisms have been proposed for tamoxifenresistance in ERa-positive breast cancer [reviewed in (6) ]. Complications arising from resistant tumor metastases are the most common cause of patient death; however, only a few genes have been shown to be essential for metastatic behavior [eg, TWIST (7) and some members of the Rho signaling pathway (8, 9) ]. The Rho family of GTP-binding proteins (RhoA-C, Rac-1, and Cdc42) regulates the polymerization of actin to 
Background
Estrogen receptor (ER) a is a successful therapeutic target in breast cancer, but patients eventually develop resistance to antiestrogens such as tamoxifen.
Methods
To identify genes whose expression was associated with the development of tamoxifen resistance and metastasis, we used microarrays to compare gene expression in four primary tumors from tamoxifen-treated patients whose breast cancers did not recur vs five metastatic tumors from patients whose cancers progressed during adjuvant tamoxifen treatment. Because Rho guanine dissociation inhibitor (GDI) a was underexpressed in the tamoxifen-resistant group, we stably transfected ERa-positive MCF-7 breast cancer cells with a plasmid encoding a short hairpin (sh) RNA to silence Rho GDIa expression. We used immunoblots and transcription assays to examine the role of Rho GDIa in ER-related signaling and growth of cells in vitro and as xenografts in treated nude mice (n = 8-9 per group) to examine the effects of Rho GDIa blockade on hormone responsiveness and metastatic behavior. The time to tumor tripling as the time in weeks from randomization to a threefold increase in total tumor volume over baseline was examined in treated mice. The associations of Rho GDIa and MTA2 levels with tamoxifen resistance were examined in microarray data from patients. All statistical tests were two-sided.
Results
Rho GDIa was expressed at lower levels in ERa-positive tumors that recurred during tamoxifen treatment than in ERa-positive tamoxifen-sensitive primary tumors. MCF-7 breast cancer cells in which Rho GDIa expression had been silenced were tamoxifen-resistant, had increased Rho GTPase and p21-activated kinase 1 activity, increased phosphorylation of ERa at serine 305, and enhanced tamoxifen-induced ERa transcriptional activity compared with control cells. MCF-7 cells in which Rho GDIa expression was silenced metastasized with high frequency when grown as tumor xenografts. When mice were treated with estrogen or estrogen withdrawal, tripling times for xenografts from cells with Rho GDIa silencing were similar to those from vector-containing control cells; however, tripling times were statistically significantly faster than control when mice were treated with tamoxifen (median tripling time for tumors with Rho GDIa small interfering RNA = 2.34 weeks; for control tumors = not reached, hazard ratio = 4.13, 95% confidence interval = 1.07 to 15.96, P = .040 [adjusted for multiple comparisons, P = .119]). Levels of the metastasis-associated protein MTA2 were also increased upon Rho GDIa silencing, and combined Rho GDIa and MTA2 levels were associated with recurrence in 250 tamoxifen-treated patients.
Study design
When microarrays were used to analyze gene expression in tumors from tamoxifen-sensitive vs tamoxifen-resistant patients, Rho guanine dissociation inhibitor (GDI) a was identified as a possible mediator of tamoxifen sensitivity. MCF-7 cells containing silencing RNA were used to examine the effects of decreased Rho GDIa expression on tamoxifen-resistant cell growth, Rho signaling, and ERa activity. The same cells were used to establish tumors as xenografts in nude mice. Last, low Rho GDIa and high expression of the metastasis-associated protein MTA2 were examined as potential biomarkers of tamoxifen-resistance among 250 patient tumors.
Contribution MCF-7 cells expressing Rho GDIa silencing RNA were tamoxifenresistant and had higher levels of Rho signaling and tamoxifeninduced ERa activity than control cells. When implanted in nude mice, these cells grew tumors even in the presence of tamoxifen, unlike control cells, and metastasized more readily. Preliminary results indicate that low Rho GDIa and high MTA2 expression may be useful clinical markers of tamoxifen-resistance.
Implications
Increased Rho, PAK1, and ERa activity by virtue of Rho GDIa inactivation appear to confer tamoxifen resistance. Consequently, inhibitors of these pathways might be useful to reverse tamoxifen resistance.
Limitations
The mechanistic experiments here were done in a single cell line, and the clinical data were based on a single, retrospective analysis. Further work in additional cell lines and a prospective clinical study will be necessary.
From the Editors
College of Medicine Institutional Review Board in accordance with federal human research study guidelines. Samples were 1) metastatic tumors from five patients whose breast cancers recurred within 11 months of the start of tamoxifen treatment (tamoxifenresistant) and 2) primary tumors, collected at the time of initial diagnosis, from four patients who were treated with tamoxifen and remained disease free for 93-123 months with a median follow-up of 106 months (tamoxifen-sensitive). The patients had received no treatments other than tamoxifen. Microarray analysis on this cohort has been previously described (14) .
Cell Culture and Transfection
The ERa-positive T47D human breast cancer cell line and HeLa human cervical cancer cell line were obtained from American Type Tissue Culture Collection (Rockville, MD). ERa-positive MCF-7 human breast cancer cells were previously described (15) . All cell lines were maintained in minimal essential medium (MEM; Invitrogen, Carlsbad, CA) supplemented with 5% fetal bovine serum (FBS; Summit Biotechnology, Fort Collins, CO), 0.1 nmol/L nonessential amino acids, 2 mmol/L l-glutamine, and 50 U/mL penicillin-streptomycin, at 37°C with 5% CO 2 and 95% air.
Tamoxifen-resistant MCF-7 cells were generated as described previously by Knowlden et al. (5) and Herman and Katzenellenbogen (16) . Briefly, we cultured parental MCF-7 cells in phenol redcontaining MEM medium supplemented with 5% FBS, antibiotics, and 10-64-hydroxy-tamoxifen (TR1 cells) or in phenol red-free MEM medium supplemented with 5% charcoal-stripped FBS, antibiotics, and 10-7M 4-hydroxy-tamoxifen (TR2 cells). Cells were continuously exposed to 4-hydroxy-tamoxifenfor 6 months during which time the medium was replaced every 4-5 days. Initially, cell growth was slow, but gradually increased, at which time the cells were designated MCF-7-TR. TR1 cells were continuously maintained in 1µM tamoxifen, and TR2 cells in 100 nM tamoxifen, for longer than 1 year.
To generate MCF-7 cells with stable silencing of Rho GDIa expression, subconfluent cells in 10-cm tissue culture dishes were transfected with 5µg of the vector carrying shRNA against Rho GDIa or 5 µg of the control vector using Fugene 6 reagent and the manufacturer's protocol (Roche, Indianapolis, IN). Stable clones of cells that contained Rho GDIa shRNA or control plasmid were selected with 1 µg/mL puromycin for 2 weeks, and positive clones in which Rho GDIa expression was silenced were identified using immunoblot analysis with a rabbit polyclonal anti-Rho GDIa antibody (1:2000; Santa Cruz Biotechnology, Inc, Santa Cruz, CA). One single-cell stable clone and a pool of stable transfectants were used in experiments. In some experiments, we used pools of T47D or tamoxifen-resistant TR1cells, both of which were stably transfected with YFP-vector and YFP-GDIa expression plasmids and selected for 1 week with G418 antibiotic (Invitrogen).
Immunoblot Analysis
Cell extracts or immunoprecipitated proteins were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) as described (13) . Antibodies used for immunoblotting were as follows: mouse monoclonal anti-ERa clone 6F11 (1:500; Vector Labs, Newcastle, UK); rabbit polyclonal anti-SRC1 (1:200; Santa Cruz Biotechnology, Inc); mouse monoclonal anti-TIF2 (1:200; BD Transduction Lab, Los Angeles, CA); mouse monoclonal anti-p190 to RASGRF1(1:500; BD Transduction Laboratories, San Diego, CA); rabbit polyclonal anti-Rho GDIa (1:2000; Santa Cruz Biotechnology, Inc); rabbit anti-MTA2 (1:2000; Sigma); mouse monoclonal anti-b-actin AC-15 (1:10 000, Sigma); rabbit polyclonal anti-ROKa (1:1000; Upstate Biotechnology, Lake Placid, NY); rabbit anti-phospho-ROKa Thr249(1:1000; Abcam, Cambridge, MA); and rabbit polyclonal anti-phospho ERa Ser305 (1:100; Millipore, Billerica, MA). Rabbit polyclonal anti-ERK1/2 (1:1000) and anti-phospho-ERK1/2 (1:500), rabbit polyclonal nuclear factor kB (NF-kB) p65 (1:1000) and rabbit polyclonal pNFkB S536 (1:1000; 93H1) were from Cell Signaling, Beverly, MA. The proteins that were transferred to nitrocellulose membranes were blocked overnight in a blocking solution (Tris-buffered saline -Tween [0.1% Tween-20; 20 mM Tris, pH 8.0; 150 mM NaCl] with 5% powdered nonfat dried milk) then incubated with primary antibodies listed above overnight at 4°C and with secondary antibodies (goat anti-mouse [1:2000] or goat anti-rabbit [1:5000] antiserum; Amersham Biosciences, Piscataway, NJ) for 1 hour at room temperature, and visualized with enhanced chemiluminescence reagents (Alpha Innotech, San Leandro, CA). Immunoblots show a single representative of at least two or three separate experiments.
Colony Formation and Soft Agar Assays
For colony formation assays, 2.5 × 10 5 TR1 or TR2 cells per well were placed in six-well tissue culture plates 24 hours before transfection. One microgram of DNA (as indicated in the individual figure legends) and Fugene 6 reagent (Roche) were used to transfect the cells in each well. Starting 24 hours after transfection, the cells were incubated for 14 days with 800 µg/mL G418 antibiotic in the specific medium used to initially generate the tamoxifenresistant cells, the colonies were stained with 1% crystal violet, and photographed under a microscope.
For soft agar assays, 5000 cells per well were plated in 4 mL of 0.35% agarose, 5% charcoal-stripped FBS in phenol red-free MEM, with a 0.7% agarose base in six-well plates. Two days after plating, medium containing vehicle or treatments as indicated was added to the top of the layer and replaced every 2 days. After 14 days, 300 µL of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT; Sigma) were added to each well and incubated at 37°C for 4 hours. Plates were then placed at 4°C overnight, and colonies larger than 50 µm in diameter were counted.
Rho GTPase Activation Assays
Cells were seeded in 10-cm plates and grown for 2 days in estrogen-deprived medium (phenol red-free MEM with 5% charcoalstripped FBS). Then, cells were washed with ice-cold PBS and lysed in MLB buffer (25 mM HEPES, pH 7.5; 150 mM NaCl, 1% IGEPAL CA-630 [Sigma], 10% glycerol, 25 mM NaF, 10 mM MgCl 2 , 1 mM EDTA, 10 mg/mL leupeptin, 10 mg/mL aprotinin, and 1 mM sodium orthovanadate). Cell lysates were clarified by centrifugation at 13 000g at 4°C for 10 minutes, and 700-1000 µg of cellular proteins were incubated with 15 µg of PAK-1 p21 binding domain (PBD) or 20 µg Rhotekin Rho binding domain (RBD) agarose conjugate (Upstate, Lake Placid, NY) at 4°C for 90 minutes. The beads were centrifuged and washed four times with MLB buffer. GTP-bound activated Rho proteins were detected by immunoblotting using mouse monoclonal antibodies against Rac-1 (1:3000); cdc42 (1:100; BD Transduction Laboratories, San Jose, CA); or rabbit polyclonal antibodies to RhoA, RhoB, or RhoC (all 1:200; from Cell Signaling).
Immunoprecipitation Assays
Immunoprecipitation assays were performed as described (17) with some modifications. High salt cell lysis buffer (15) with 1:100 diluted complete proteinase inhibitor III solution (Roche) was used to prepare cellular extracts, which were then adjusted to 150 mM NaCl plus 1.0% NP-40 (binding buffer) and incubated with 1-2 µg of the appropriate antibody as indicated. After centrifugation and washing four times with the lysis buffer, the precipitated components were eluted by boiling in SDS loading buffer, resolved by SDS-PAGE, and analyzed by immunoblotting. p21-Activated Kinase 1 (PAK1) Immunocomplex Kinase Assay Cells (3 × 10 6 ) were plated in 10-cm dishes with MEM supplemented with 10% FBS and incubated for 24 hours at 37°C in 5% CO 2 .Cells were then serum-starved for 48 hours in phenol redfree MEM before lysis in 50 mM HEPES (pH 7.0), 150 mM NaCl, 1 mM MgCl 2 , 1 mM EGTA, 10 mM NaPO 4 , 1% glycerol (vol/vol), 0.1% Triton X-100 (vol/vol), 1 mM Na 3 VO 4 , and 1:100 protease inhibitor cocktail tablet. Immunocomplex kinase assays were done with PAK1 protein immunoprecipitated from 200 µg of total cellular protein using 2 µg of rabbit polyclonalanti-PAK1 antibody (Santa Cruz Biotechnology, Inc) with rotation at 4°C for 2 hours. Immunoprecipitated pellets were washed three times with immunocomplex kinase assay wash buffer (0.1% Triton X-100, 150mMNaCl, and 10mM NaPO 4 [pH 7.0]). Ten micrograms of purified GST-ERa hinge domain protein, described previously (13) , was added to the immunoprecipitated pellets in 20 µL kinase reaction buffer containing 20 mM HEPES (pH 7.0), 6 mM MgCl 2 , 20 mM Na 3 VO 4 , and 10 µCi [g -32 P]-ATP (3000 Ci/mmol; NEN, Boston, MA) and incubated for 20 minutes at 22°C. The reaction was stopped by the addition of SDS loading buffer. The samples were resolved using SDS-PAGE and transferred onto nitrocellulose membranes. The input GST-ERa hinge domain proteins were visualized with Ponceau S staining, the levels of ERa phosphorylation were determined by autoradiography, and the immunoprecipitated PAK1 was detected by immunoblot with a rabbit polyclonal anti-PAK1 antibody (1:1000; Santa Cruz Biotechnology, Inc).
ERa Transactivation Assays
Cells were maintained in phenol red-free MEM supplemented with 5% charcoal-stripped FBS (Hyclone, Logan, UT) for 5-7 days. One day before transfection, 2.5 × 10 5 MCF-7 or T47D cells or 0.5 × 10 5 HeLa cells were plated in 2 mL medium per well in six-well plates and then transfected using Fugene 6 reagent (Roche) following the manufacturer's protocol. The cells in each well were transfected with ERE-luciferase reporter, pCMVb-galactosidase vector, and YFP-GDIa and/or ERa expression vectors as indicated. After 24 hours, cells were treated with estrogen (102 9 M), 4-hydroxy-tamoxifen (102 7 M) or vehicle as indicated in the figure legend for an additional 18-24 hours. Luciferase activity was assessed using the Luciferase Assay System (Promega) following the manufacturer's protocol.
Xenograft Studies
MCF-7 vector control cells and a Rho GDIa shRNA stably transfected clone were established as xenografts in ovariectomized 5-to 6-week-old BALB/c athymic nude mice (Harlan Sprague Dawley, Madison, WI) by inoculating the mice subcutaneously with 5× 10 6 cells in 100 µL of medium with 100 µL of Matrigel (BD Biosciences, San Jose, CA), as described previously (18) . The mice were supplemented with 0.72 mg 60 day-release estradiol pellets that were implanted subcutaneously between the shoulder blades (Innovative Research, Sarasota, FL). Tumors were measured with calipers three times per week. When tumors reached approximately 250 mm 3 (ie, in 1.5-2.5 weeks), the mice were randomly allocated to continue estradiol (n = 8-9 mice per group) or to estrogen withdrawal plus tamoxifen (n = 7-8 mice per group; estradiol pellets were removed and 500 µg/d of tamoxifen was given to each mouse subcutaneously in peanut oil, on each of 5 d/wk) for another 30 days. Tumor growth was assessed, and tumor volumes were measured as described previously (18) . Mice were killed when moribund or when the tumor burden exceeded 1 cm 3 . Animal care was maintained in accordance with institutional guidelines.
Immunohistochemistry
Immunohistochemistry was performed by the Breast Center Pathology Core facility at Baylor College of Medicine, Houston, TX. Lung metastases arising from xenografts of Rho GDIa shRNA-containing MCF-7 cells were fixed overnight in 10% formalin buffered in methanol, followed by paraffin embedding. Thin (5 µm) sections were stained with hematoxylin and eosin (H&E). For detection of ERa and progesterone receptor, thin sections of formalin-fixed paraffin-embedded tissues were deparaffinized and rehydrated from xylene through a graded series of ethanol washes. Antigen retrieval was carried out by boiling in Tris-Cl (pH 9.0) in a standard pressure cooker for 20 minutes. Endogeneous peroxidases were blocked by treatment with 3% hydrogen peroxide in methanol. Protein blocking was performed with Avidin Solution A (A/B blocking Kit; Vector Laboratories, Burlingame, CA) according to manufacturer's protocols. Slides were incubated with mouse anti-ERa 6F11 antibody (1:200; Vector Labs) or mouse anti-PR (1:1600, PgR1294; Dako, Inc, Carpinteria, CA) for 1 hour at room temperature, followed by a horseradish peroxidase-conjugated secondary antibody, and horseradish peroxidase was detected with diaminobenzidine tetrahydrochloride (Invitrogen), and counterstained with Gills hemotoxylin. Images were captured on a Zeiss Axioskop 2 plus microscope with a Canon Powershot G5 camera.
Invasion Assay
CTRL sh and GDIa sh cell invasion was determined using 24-well BD Biocoat invasion chambers (Bedford, MA) containing 8-µm porous membranes precoated with Matrigel. Cells were serumstarved for 2 days. The cells were removed from the plate with warm versene (Lonza, Switzerland) and 100 000 cells were seeded into the chambers in serum-free phenol red-free MEM (Invitrogen) with or without 17b-estradiol (E, 102 9 M), 4-hydroxy-tamoxifen (T, 102 7 M), or the ROK inhibitor Y-27631 (R, 102 8 M). Chemoattractant, or medium containing 10% FBS, was added to the lower compartment. After 22 hours incubation at 37°C, the noninvasive cells and Matrigel were removed from the inside of the wells with a cotton swab. The invading cells were then fixed with Diff-Quik Fixative and stained with Diff-Quik Stain Solution I and II (Siemens, Aktiengesellschaft Erlangen, Germany). Finally, the membranes were removed from the chambers using a scalpel blade and mounted onto glass microscope slides, and cell invasion was quantified by counting the number of cells per membrane at ×20 magnification. Data were then plotted as mean number of cells in triplicate. Error bars correspond to 95% confidence intervals; P values were calculated using two-sided Student t tests.
Statistical Analyses
Three major types of statistical analysis were used to analyze data for this study: those for the cell line experiments, for xenograft data, and for analysis of a breast tumor dataset that was previously described by others (see below). In all cases, P values less than .05 were considered to denote statistical significance, and all statistical tests were two-sided. For cell line experiments, statistical differences (P values) among groups were obtained using a two-sided Student t test with GraphPad Prism 5 software (GraphPad Software, San Diego, CA).
The xenograft experiments were analyzed using survival analysis methods to address the main question of whether, in the absence of tamoxifen, the tumors that arose from cells with Rho GDIa shRNA grew faster than those that arose from cells containing only the empty vector and whether they were resistant to tamoxifen. We tested the hypothesis that decreased Rho GDIa expression would render cells resistant to the growth inhibitory effects of tamoxifen. We calculated the time to tumor tripling as the time in weeks from randomization to a threefold increase in total tumor volume over baseline. Time to tumor tripling is a direct way to assess differences in tumor growth rate, without explicitly modeling tumor growth (which requires a common model structure across all groups). Survival curves were computed by the KaplanMeier method and compared with the two-sided log-rank test. Wald 95% confidence intervals for the proportion of mice that were tumor-tripling free at 4 and 8 weeks were computed using the standard error of the survival function at the maximum event time less than or equal to 4 (or 8) weeks. Individual comparisons, after rejection of the global null hypothesis, were tested using contrasts in the context of a Cox regression. We used visual inspection of a graphical examination of log-log(s) plots to feel comfortable that the assumptions of proportionality were confirmed for the Cox analysis. Exponentiation was used to calculate the upper and lower limits of Wald 95% confidence intervals of the corresponding regression coefficients. P values were adjusted by the method of Holm (19) . Analyses were carried out using SAS (V9.2; Cary, NC) and R (Version 2.9.2) (20) .
To test the effects of Rho GDIa and MTA2 in retrospective clinical samples, we used the dataset previously described by Loi et al. (21) , available at the Gene Expression Omnibus (GEO) repository (http://www.ncbi.nlm.nih.gov/geo), accession number GSE6532. The probe sets 213606_s_at, 201168_x_at, 201167_x_at, and 211716_x_at were averaged to represent the expression of Rho GDIa, and 203444_s_at was used to represent the expression of MTA2. Clinical data were matched to the expression data for all 255 tamoxifen-treated samples in the Loi et al. training dataset in the GEO database and samples that were not ERa positive or that were missing expression data were excluded, resulting in the inclusion of samples from 250 ER-positive tamoxifen-treated patients. Optimum cut points for the analyses were calculated using a bootstrapping approach wherein the x 2 statistic was calculated using the two-sided log-rank test for each of a range of cut points on each of 500 bootstrapped samples. From these x 2 statistics, the median x 2 statistic was obtained for each cut point and used to select the cut points presented here. Because this dataset contains samples from many institutions and studies (21), we compared the proportion of samples that were RhoGDIa low and MTA2 high in each study with that of all other patients using the two-sided x 2 test and found no difference in study proportions in these populations, indicating that the observed survival difference was not caused by a study bias. The statistical program R with the package Survival was used to analyze the Loi dataset (20) . Survival curves were compared using log-rank tests.
Results

Rho GDIa Loss and the Acquisition of a TamoxifenResistant Phenotype
To identify genes whose expression is associated with the development of tamoxifen resistance, we used microarrays to compare gene expression in four primary tumors from patients treated with tamoxifen whose breast cancers did not recur during extended follow-up (in >93 months), with that in five metastatic tumors from patients whose breast cancers progressed during tamoxifen treatment (in <11 months).We have already reported finding novel mechanisms of tamoxifen resistance in this cohort that involve mitogen-associated protein kinase phosphatase 3 (MKP3) and tamoxifen-induced oxidative stress (14) and overexpression of the androgen receptor (AR; 22). Accordingly, cluster analysis showed that both MKP3 and AR were overexpressed in these tamoxifenresistant tumors (Figure 1, A) .
Multiple resistance mechanisms could be operating in tamoxifen-resistant patients. Levels of Rho GDIa were statistically significantly reduced in tamoxifen-resistant tumors as compared with tamoxifen-sensitive tumors (P = .017; Figure 1 , B). Because lower levels of the Rho GDIs have been associated with metastasis (12), we established clones of ERa-positive MCF-7 cells, which have low metastatic potential (23) that were stably transfected with a plasmid encoding a Rho GDIa shRNA (GDIa sh) or a scrambled control shRNA (CTRL sh).We also generated a pool of MCF-7 cells that stably expressed the Rho GDIa shRNA (GDIa sh POOL). Expression of GDIa protein was efficiently silenced in both the cloned and pooled GDIa sh-transfected cells (Figure 1,  C) . We examined anchorage-independent growth using soft agar assays ( Figure 1, D) ; the growth of cells transfected with vector alone was enhanced with estrogen and inhibited with tamoxifen, whereas pooled or cloned cells containing GDIa shRNA grew better under basal hormone-independent conditions and were further growth-stimulated with either estrogen or tamoxifen, thus demonstrating tamoxifen insensitivity. Similar results were seen in cells grown in culture using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) growth assays (Supplementary Figure 1, available online) .
We next generated a stable pool of cells in which we "rescued" GDIa expression by transfecting cloned GDIa sh-containing cells with a mutant version of Rho GDIa that was resistant to small interfering RNA interference (Figure 1, E) . CTRL sh cells and rescued cells were growth-inhibited with tamoxifen, whereas GDIa sh cells were insensitive to tamoxifen-mediated growth inhibition (Figure 1, F) , but still sensitive to growth inhibition by the anti-estrogen ICI 182780, also called fulvestrant. We hypothesized that the requirement of Rho GDIa expression for tamoxifen sensitivity may be dependent on sustained ERa expression because fulvestrant, which inhibits growth, degrades the ERa protein (24) . Tamoxifen-resistant growth of the GDIa sh clone was blocked in the RESCUE cells, confirming the role of Rho GDIa in tamoxifen action.
To explore the relationship between Rho GDIa levels and tamoxifen resistance, we generated two tamoxifen-resistant MCF-7 sublines (TR1 and TR2) using long-term exposure to tamoxifen. Rho GDIa levels were lower in both sublines compared with parental cells (Figure 2, A) . We transfected both cell lines with YFP-vector or YFP-Rho GDIa plasmids and examined colony formation efficiency (Figure 2, B) . Both tamoxifen-resistant sublines formed colonies in the presence of tamoxifen, but when these cell lines were transfected to express YFP-Rho GDIa, the colonies were greatly reduced in size and numbers. We used growth assays to examine the properties of tamoxifen-resistant cells with stable reexpression of YFP-GDIa (Figure 2, C and D) . TR1 cell growth Figure 1 . Rho guanine dissociation inhibitor (GDI) a expression and resistance to tamoxifen. A) Clustering analysis of selected gene expression patterns in tamoxifen-resistant vs tamoxifen-sensitive breast cancers. Rho GDIa, AR, and MKP3 expression were measured by microarray analysis of mRNA from primary breast cancer tissue from patients whose tumors were tamoxifen-sensitive (TS, n = 4) and from metastatic breast cancer tissue from patients whose tumors were tamoxifen-resistant (TR, n = 5). Relative gene expression between the two groups is represented by color, with red indicating high and blue indicating low levels of expression. B) Statistical analysis of Rho GDIa RNA expression in the four tamoxifen-sensitive and five tamoxifenresistant breast tumors shown in (A). There was a statistically significant difference in Rho GDIa expression between tamoxifen-resistant and tamoxifen-sensitive cells (P = .017, two-sided t test). C) Silencing of Rho GDIa expression in MCF-7 cells. Immunoblot (IB) of whole-cell lysates from MCF-7 cells stably transfected with either a scrambled shRNA (CTRL sh) or Rho GDIa shRNA (GDIa sh), or from a pool of MCF-7 cells stably expressing the Rho GDIa shRNA (GDIa sh POOL). Blots were cut and rabbit polyclonal antibodies recognizing Rho GDIa were used to probe one portion of the membrane, and a mouse monoclonal antibody to b-actin (ACTIN), as a loading control, on the other. D) Anchorage-independent growth and tamoxifen sensitivity of MCF-7 cells with and without Rho GDIa silencing. CTRL sh, GDIa sh, and GDIa sh POOL cells were seeded (5000/well) in 0.35% agarose and then treated with 17b-estradiol (E, 10 -9 M), 4-hydroxy-tamoxifen (T, 10 -7 M), or vehicle (C). Cells were allowed to grow for 14 days and the numbers of colonies that were larger than 50 µm were counted. The graphs represent the mean colony number on three plates from each of three independent experiments. Error bars correspond to 95% confidence intervals. P values were calculated using two-sided Student t tests. For C treatment between CTRL sh and GDIa sh, **P = .004 and between CTRL sh and GDIa sh POOL, **P = .006. For C vs E and C vs T in CTRL sh cells, ***P = .001 and *P = .020, respectively. For C vs E and C vs T in GDIa sh cells, *P = .027 and n.s. (not significant), respectively. For C vs E and C vs T in GDIa sh POOL, ***P < .001 and ***P < .001, respectively. E) Rescue of Rho GDIa expression. GDIa sh-containing MCF-7 cells were transfected with a silencing-resistant version of Rho GDIa, YFP-GDIa. Whole-cell lysates from CTRL sh, GDIa sh, and the RESCUE clone were immunoblotted. Rabbit polyclonal antibodies recognizing Rho GDIa were used to evaluate its expression on one portion of the blot, and a mouse monoclonal antibody to p190 RASGRF1was used to probe the other portion to ensure equal loading. F) Anchorageindependent growth and tamoxifen and fulvestrant sensitivity of GDIa sh vs rescue cells. CTRL sh, GDIa sh and RESCUE clones were plated in soft agar and then treated with 17b-estradiol (E, 102 9 M), 4-hydroxy tamoxifen (T, 102 7 M), fulvestrant (ICI 182780, I, 102 8 M), or vehicle (C). Data are the mean colony number from three plates and are representative of two independent experiments. Error bars correspond to 95% confidence intervals. P values were calculated using two-sided Student t tests. For C vs T in CTRL sh, GDIa sh, and RESCUE cells, *P = .01, P = n.s. (statistically nonsignificant), and **P = .002, respectively.
was not inhibited with tamoxifen. However, when Rho GDIa was stably reexpressed, the basal growth of TR1 cells was decreased and they became tamoxifen-sensitive. These results suggested that Rho GDIa levels may be a major determinant of tamoxifen resistance in ERa-positive cells.
Effect of Rho GDIa Silencing on Rho and ERa Signaling
To study mechanism, we first examined the activation of Rho family of GTPases using GST-pulldown assays ( The Rho GTPases activate downstream effectors (25) . Either activation or increased expression of one effector, PAK1, can render breast cancer cells tamoxifen-resistant (26, 27) . Protein kinase A and PAK1 kinase signal to and phosphorylate ERa at serine (S) 305 (13, 28, 29) . Therefore, we examined PAK1 activation by immunoprecipitating PAK1 from cells with and without Rho GDIa expression and using purified GST-ERa protein (residues 253-310) as substrate (Figure 3, B) . We found higher levels of phosphorylated ERa in Rho GDIa shRNAcontaining cells. When we mutated the serine 305 residue of ERa to an alanine (S305A), we found no phosphorylation by PAK1. Expression of Rho GDIa shRNA also led to enhanced phosphorylation of ERa at S305 (Figure 3, C) . Phosphorylation of ERa at S305 can enhance sensitivity to estrogen treatment (13, 29) and predicts poor response to tamoxifen in breast cancer patients (30) . Thus, increased PAK1 activity in cells with decreased Rho GDIa expression may lead to enhanced phosphorylation of a site on ERa that is critical for resistance to tamoxifen.
Phosphorylation of ERa S305 by PAK1 and phosphorylation of ERa S118 by MAPK may be linked (28) . We observed constitutive activation of pMAPK in GDIa sh cells, but not elevated levels of ERapS118 with tamoxifen (Figure 3, D) . We observed elevated pS118 levels in both cells with estrogen as expected (31) . Thus, phosphorylation of ERa S305 and S118 are not coupled with tamoxifen treatment in our model, and elevated pMAPK levels might be a consequence of increased activation of PAK1 in cells with decreased GDIa expression.
Rho GDIa and ERa interact in MCF-7 cells (32). We next examined how tamoxifen affected their interaction by immunoprecipitation of ERa and immunoblotting for Rho GDIa in the presence of estrogen or tamoxifen (Figure 3, E) . We observed an estrogen-dependent interaction between ERa and the transcription intermediary factor 2 (TIF2, an ERa coactivator protein used as a control) as reported previously (15) . We observed an interaction between Rho GDIa and ERa under control and estrogen treatments but not with tamoxifen. We conclude that Rho GDIa probably does not enable tamoxifen sensitivity by direct binding to ERa in tamoxifen-treated cells.
Because phosphorylation of ERa at S305 has been reported to block acetylation of ERa at lysines (K) 302 and 303 (13), we also used Error bars correspond to 95% confidence intervals. P values were calculated using two-sided Student t tests. For vehicle-treated TR1 YFPGDIa vs vehicle-treated TR1 YFP cells, * P = .04. For C vs T in TR1 YFP and TR1 YFP-GDIa, n.s. = statistically nonsignificant, and **P = .007, respectively.
immunoblots to check whether ERa could be immunoprecipitated with an anti-acetyllysine antibody from lysates of cells with decreased Rho GDIa expression. We found lower levels of acetylated ERa in GDIa sh cells (Figure 3, F) , whereas the acetylation of the ERa coactivator SRC-1 (a positive control) was unchanged. When Rho GDIa sh cells expressing ERa S305A were used in these experiments, acetylation of ERa was restored in the S305A mutant ( Figure  3, G) . These results suggest that the hinge region of ERa, which contains the important regulatory residues, K302, K303, and S305, is altered concomitant with Rho GDIa silencing.
Effect of Rho GDIa on ERa Transactivation
Because Rho GDIa overexpression and PAK1 activation had been reported to enhance ERa transcriptional activity (27, 33) , we transfected three human cell lines (MCF-7 and T47D breast cancer cells, and HeLa cervical cancer cells) with YFP-GDIa and a luciferase reporter plasmid from which transcription could be activated through an estrogen response element. Because HeLa cells were ER-negative, they were also transfected with an ERa expression vector. In all cells tested, Rho GDIa overexpression decreased estrogen-induced transactivation (Figure 4 , A-C). We also tested the effect of Rho GDIa expression on ERa activity in stable pools of T47D cells overexpressing YFP-Rho GDIa. ERa activity was decreased with estrogen but not affected by tamoxifen in these cells (Figure 4 , D and E). In keeping with these results, estrogenand tamoxifen-induced ERa activity was enhanced with Rho GDIa silencing (Figure 4, F) . These data demonstrate that Rho GDIa expression is inversely related to ERa activity. The reason for the differences in our results compared with those of some others (32,33) is not presently understood; however, the cell lines Rho binding domain (RBD) agarose conjugate at 4°C for 90 minutes and separated by centrifugation. GTP-bound activated Rho proteins were detected by immunoblotting using mouse monoclonal antibodies against Rac-1 and cdc42; or rabbit polyclonal antibodies to RhoA, RhoB, or RhoC. Whole-cell lysates were used as input controls (INPUT). Blots are representative of three independent experiments. B) Activation of PAK1 in cells with reduced Rho GDIa expression. Immunocomplex kinase assays were performed using purified GST-ERa fragments (aa 253-310) as the substrate and using PAK1 that was immunoprecipitated (IP) from CTRL sh, GDIa sh, and RESCUE clones as the enzyme. An ERa GST-fragment in which the serine 305 phosphorylation site was converted to an alanine (S305A) was used as negative control. Phosphorylated ERa levels ( were different and it is possible that the data were normalized differently.
Effect of Rho GDIa Silencing on Tamoxifen-Resistant Growth and Metastasis of Xenografts
To examine the effects of decreased Rho GDIa expression on tumor growth in vivo, we next injected MCF-7 cells containing Rho GDIa shRNA or the empty vector into athymic nude mice. Mice were implanted with 60-day release estrogen pellets, and at approximately 1.5-2.5 weeks, when tumors reached approximately 250 mm 3 , the mice were randomized to continue estrogen (E), to have estrogen withdrawn (ie, the pellet removed; N), or to have estrogen withdrawn and to begin tamoxifen treatment (T). Xenograft tumor growth is shown in Supplementary Table 1  (available online) .
Our results were consistent with tamoxifen-resistance among tumors from cells with Rho GDIa silencing. Among mice that carried tumors derived from CTRL sh cells, the time to tumor tripling in the presence of tamoxifen treatment (VT) was not statistically significantly different from that in the presence of estro- To summarize, when mice were treated with estrogen or estrogen withdrawal, xenografts derived from Rho GDIa shRNAexpressing cells (RE or RN) tripled in size at about the same rate as those derived from vector control cells (VE or VN). However, when the mice were treated with tamoxifen, xenografts from cells with Rho GDIa silencing (RT) tripled in size at a statistically significantly faster rate compared with those derived from vectorcontaining cells (VT).These data provide strong evidence that Rho GDIa silencing can confer tamoxifen resistance in vivo.
Most strikingly, two of eight (25%) examined lungs from the tamoxifen-treated vs three of five (60%) estrogen-treated mice that carried tumors derived from GDIa sh cells carried metastases within 3 months. For example, in a representative H&E slide from the lung of an estrogen-treated mouse carrying a GDIa sh cellderived tumor, three metastases can be seen in a single section ( Figure 5, B, arrows) . MCF-7 infrequently metastasizes to distant organs (23) , and none of the mice carrying tumors derived from vector-only cells developed metastases during this experiment. 
(ER) a transcriptional activity. A-C)
Effect of transient Rho GDIa expression on estrogen-stimulated luciferase reporter activity. MCF-7 (A) and T47D (B) cells were cotransfected with an estrogen response element (ERE)-luciferase reporter, a pCMVb-galactosidase vector, and the yellow fluorescence protein (YFP)-GDIa vector. The ERa-negative HeLa cells (C) were also cotransfected with a wild-type ERa expression vector. Cells were treated with estrogen (E, 102 9 M) and after 18-24 hours, cell lysates were harvested. ERE-luciferase activity was measured and normalized by dividing by the b-galactosidase activity to give relative luciferase units. The data are representative of three independent experiments, each performed in triplicate, and are reported as fold induction. For E treatment between GDIa and YFP-expressing MCF-7 cells (A), T47D cells (B) and Hela cells (C), *P = .004, **P = .041, and *P = .041 and *P = .003, respectively. D) Creation of stable pools of T47D cells overexpressing the YFPvector (YFP-V) or YFP-Rho GDIa (YFP-GDIa). Whole-cell lysates were immunoblotted and probed with a rabbit polyclonal anti-Rho GDIa antibody. E) Estrogen-stimulated luciferase reporter activity in T47D cells with and without YFP-Rho GDIa expression. ERE-luciferase activity was assayed in stable pools of T47D cells overexpressing the YFP-vector (YFP-V) or YFP-Rho GDIa (YFPGDIa) and treated with 17b-estradiol (E, 102 9 M), 4-hydroxy-tamoxifen (T, 10 -2 7 M), or vehicle (C). Data are representative of three independent experiments, each performed in triplicate, and reported as fold induction. For E treatment between YFP-V and YFP-GDIa stable pools, *P = .012. F) Effect of Rho GDIa silencing on estrogen and tamoxifeninduced ERa transcriptional activity. ERE-luciferase activity was measured in stable CTRL sh and GDIa sh clones treated with 17b-estradiol (E, 102 9 M), 4-hydroxy-tamoxifen (T, 102 7 M), or vehicle (C). Data are representative of three independent experiments, each performed in triplicate, and are reported as fold induction. For E and T treatments between CTRL sh and GDIa sh,***P < .001. For panels (A-C), (E), and (F), error bars correspond to 95% confidence intervals and P values were calculated using two-sided Student t tests.
Thus, Rho GDIa silencing enhanced metastasis. The metastases probably have an intact hormone response pathway, not only because their growth was stimulated by both estrogen and tamoxifen but also because tumors in the estrogen-treated group were positive for the estrogen-responsive progesterone receptor ( Figure 5, C) . Because estrogen treatment results in decreased ERa protein levels (34), we did not see ERa expression in the metastases (Figure 5, D) . These results are important because there are few preclinical models of hormone-responsive metastases, and breast cancer metastasizes to the lung more frequently than to any other site but bone. About half of lung metastases are ERa-positive (35) .
Among other downstream effectors of Rho signaling, the Rhoassociated kinases (ROKs) and NF-kB, are important for cell motility and invasion (36) (37) (38) (39) . Although we did not observe NF-kB activation (Supplementary Figure 3, A and B , available online), we detected elevated levels of activated ROKa in cells containing Rho GDIa shRNA ( Figure 5, E) . It has been suggested that estrogen promotes an epithelial-to-mesenchymal-like transition that would foster cellular invasion (40) . Consistent with this idea, when we measured cell invasion in modified Boyden chamber assays, we saw enhanced invasion by estrogen-treated CTRL sh cells compared with untreated cells (Figure 5, F) . In cells with decreased Rho GDIa expression, we saw enhanced constitutive and estrogen-stimulated invasion. Tamoxifen also enhanced invasion, suggesting that tamoxifen is acting as an ERa agonist. ROK inhibition by treatment with Y-27632 reduced basal growth and blocked tamoxifen-stimulated invasion only in cells in which Rho GDIa expression was decreased. It is known that many metastasis suppressor genes do not affect primary tumor growth, but only metastatic processes such as motility and invasion (9) . Therefore, we tested the ROK inhibitor in anchorage-independent assays ( Figure 5, G) .Treatment with the ROK inhibitor Y-27632 did not affect basal growth cells with decreased Rho GDIa expression, and it did not restore tamoxifen-sensitive growth. This suggests that the ROK inhibitor's activities might be restricted to the invasive potential of these cells but not useful to block tamoxifen's agonistlike effects on growth.
Association of Combined Rho GDIa and MTA2 Status With Clinical Outcomes
The metastasis-associated protein (MTA) family is associated with breast tumor progression and ERa activity (41) . We demonstrated that MTA2 overexpression in ERa-positive cells generated a tamoxifen-resistant phenotype (42) . To explore the metastatic phenotype associated with Rho GDIa silencing, we performed immunoblot analysis and found an increase in MTA2 protein levels in cells with decreased Rho GDIa expression compared with CTRL sh cells (Figure 6, A) . The increase in MTA2 levels was independent of estrogen and tamoxifen treatment. An immunoblot analysis of six primary breast tumors showed that levels of both proteins varied among the tumors (Figure 6, B) .
To assess the clinical significance of Rho GDIa and MTA2 expression levels, we analyzed a microarray dataset described by Loi et al. (21) , GSE6532. To determine the effects of Rho GDIa and MTA2 on the response to tamoxifen, only data from the 250 patients who were classified as ER+ and who received tamoxifen monotherapy were considered. On the basis of the microarray data, we subdivided patients in the tamoxifen-treated group into a Rho GDIa low and MTA2 high ("low/high") group vs all other groups using a bootstrapping approach to select optimum cut points. Of the 250 patients, 51 were classified as "Rho GDIa low and MTA2 high" and 199 were classified as "Others". The patients were similar in terms of nodal status, histological grade, age, and tumor size (Supplementary Table 2 , available online). In the tamoxifen-treated group, the low/high patients (n = 51) had a statistically significantly poorer recurrence-free survival compared with all other patients ( Figure 6 , C, P = .023 [log-rank test, Coxproportional hazards, HR = 5.84, 95% CI = 1.15 to 2.99]). No difference in survival was observed when patients were subdivided based on expression of Rho GDIa or MTA2 alone in the treated group. We performed the same analysis on the samples classified as tamoxifen-untreated also in the Loi dataset and found no difference in recurrence-free survival; however, the number of untreated patients was small precluding a definitive conclusion about prognosis (data not shown). We hypothesize that low levels of Rho (T, 102 7 M), or vehicle (C) for 24 hours before lysis. Levels of Rho GDIa (rabbit polyclonal antibody to Rho GDIa) and rabbit polyclonal antibody to MTA2 were analyzed in cellular extracts by immunoblot analysis (IB). Mouse monoclonal antibody to b-actin (ACTIN) was used as a control for equal loading and transfer. The immunoblots are representative of three separate experiments. B) Rho GDIa and MTA2 expression in six breast tumors. Protein extracts from six breast tumors were analyzed for Rho GDIa and MTA2 expression using immunoblot analysis (IB). b-actin (ACTIN) was used as a control for equal loading and transfer. C) Rho GDIa and MTA2 expression and clinical outcome in tamoxifen-treated patients. The proportion of patients remaining diseasefree is shown using Kaplan-Meier plots of survival data from tamoxifentreated estrogen receptor a-positive patients from the Loi et al study (21) stratified by low Rho GDIa and high MTA2 RNA levels. The number of events and patients in each group are shown (P = .011, log-rank test, Cox-proportional hazards, hazard ratio = 5.84, 95% confidence interval = 1.149 to 2.988).
GDIa expression may predict poor outcome among tamoxifentreated patients, potentially through its effects on metastatic pathways such as MTA2.
Our working model ( Figure 7 ) is that loss of Rho GDIa expression enhances metastasis and tamoxifen resistance via effects on both ERa and MTA2. Decreased expression or loss of Rho GDIa subsequently causes release of bound Rho family members (RhoA-C, Cdc42, and Rac-1), leading to the subsequent activation of its downstream effectors, including PAK1 and ROK. Activated PAK1, either directly or indirectly, leads to ERa phosphorylation at S305, which inhibits ERa acetylation by shifting the conformation of ERa thus altering hormone response. ROK activation enhances cell motility, invasiveness, and metastasis. Rho GDIa loss also enhances MTA2, which can participate both in metastasis and tamoxifen resistance.
Discussion
We demonstrate that Rho GDIa silencing affects pathways that affect both the metastatic phenotype and hormone responsiveness of breast cancer cells. Despite recent advances with antihormonal therapies, the median survival of patients with metastatic breast cancer is very poor-only 2-3 years (43). Thus, resistance to hormonal therapies continues to be a major clinical problem. The ERa status of metastases does not always correlate with that of the primary tumor (4,44), but it has been shown that ERa expression was lost in only 17% of tamoxifen-resistant tumors as compared with expression in the primary tumor of each patient (45) , so that sustained ERa expression and function are probably important for hormone resistance.
One major mechanism that has been proposed for resistance is enhanced bidirectional cross talk between ERa and growth factor receptor pathways, as ERBB2 (46) . Another emerging mechanism involves the activation of intracellular signaling molecules that can either circumvent growth dependence on ERa (47) (48) (49) or augment ER's function (49) . Therefore, selectively inhibition of intracellular signal transduction is a promising new method to target tamoxifen-resistance in patients (50) . In our pilot cohort of tamoxifen-resistant patients, it appeared that multiple mechanisms of resistance could occur simultaneously. Our identification of a role for Rho GDIa in ERa action, tamoxifen resistance, and metastatic behavior further underscores the potential for inhibitors of signal transduction to overcome tamoxifen resistance in breast cancer. If multiple mechanisms of resistance occur in patients, then a combination of therapeutics targeted to multiple pathways may be required for effective treatment.
The acquisition of a remodeled cytoskeleton and a motile invasive phenotype are important steps in metastasis, and the Rho GTPases mediate these processes [reviewed in (51) ]. Several reports have demonstrated a connection between pathways that regulate the cytoskeleton and hormone resistance in breast cancer. Tamoxifen treatment has been reported to alter the localization of actin and fibronectin receptors, and actin skeleton remodeling in endometrial cells (52) . Furthermore, overexpression of the Ras-GDP exchange factor AND-34/BCAR3, which associates with the focal adhesion protein p130Cas, has been reported to alter actin distribution, and to confer tamoxifen-resistant growth (53) .
Here, we examined whether loss of a negative regulator of the Rho GTPases could affect hormone response. By comparing tamoxifen-sensitive primary tumors with metastatic tumors that recurred while the patients were undergoing tamoxifen treatment, we discovered lower levels of Rho GDIa RNA in the resistant tumors. By contrast to other laboratories that used tumors that developed before tamoxifen treatment (54,55), we used tumors that developed during tamoxifen treatment, with the hypothesis that mechanisms of resistance might differ under tamoxifen selection. Indeed, our study of one tumor from this cohort revealed that overexpression of the MAPK phosphatase MKP3 conferred tamoxifen resistance in breast cancer cells (14) . We might not have identified MKP3 as a determinant of resistance if we had not screened tumors that appeared during tamoxifen treatment because tamoxifen induced altered MKP3 expression via induction of reactive oxygen species and altered MKP3 expression was among the genes associated with tamoxifen resistance in primary breast tumors (56, 57) .
It has been shown that the kinase PAK1 phosphorylates ERa and that nuclear PAK1 localization is associated with tamoxifen resistance in breast cancer patients (27, 58) . PAK1 expression might be intricately interwoven with the metastasis resistance phenotype associated with Rho GDIa shRNA expression. It is also possible that the ERa S305 site, a target of PAK1 phosphorylation, is a major determinant of tamoxifen resistance as has been suggested by Michalides et al. (29, 58) . The S305 site is a factor in resistance to both tamoxifen and aromatase inhibitors via cross talk with growth factor signaling pathways in cells expressing somatic ERa K303R mutations (59) (60) (61) .This mutation was associated with poor outcomes in univariate analyses of tumors from untreated breast cancer patients, and its presence was correlated with older age, larger tumor size, and lymph node-positive disease. Molecular analyses of the K303R ERa mutation have shown that the mutated Activated ROK may enhance cell motility and invasion. Activated PAK1 may phosphorylate ERa at serine (S) 305 and inhibit its acetylation, thus inducing tamoxifen resistance (TR). Loss of Rho GDIa is also associated with enhanced MTA2 expression, which can induce both metastasis and TR.
arginine at the 303 position allows ERa to be more highly phosphorylated by protein kinase A (PKA) and Akt kinase signaling (61, 62) and alters the dynamic recruitment of coactivators and corepressors, such as BRCA-1 (63) . Overexpression of the K303R mutation in ERa-positive MCF-7 breast cancer cells conferred increased sensitivity to subphysiological levels of estrogen and decreased sensitivity to tamoxifen treatment when engaged in cross talk with growth factor receptor signaling pathways (60) . Expression of the K303R ERa mutation also conferred resistance to the nonsteroidal aromatase inhibitor anastrozole in ERapositive cells (59, 61) . In these studies, blocking ERa S305 phosphorylation ablated tamoxifen resistance and cross talk between the ERaK303R mutant and the ERBB2 and IGFR signaling pathways (59, 61) . Our results suggest that the development of specific PAK1 (64) and ROK inhibitors might be useful to reverse tamoxifen resistance.
Low Rho GDIb is associated with increased metastasis risk and decreased survival in patients with locally advanced bladder cancer (65) . Both endothelin-1 and neuromedin U are mediators of Rho GDIb effects on metastasis and tumor progression (66, 67) . Here, we report that MTA2 may be a mediator of Rho GDIa's effects on metastasis and tumor progression in patients. The MTA family is important to ER function and ER-associated pathology [for a review, see (68) ]. MTA2 can act as a negative corepressor of ERa action leading to hormone-independent growth (42) . Expression of GDIa shRNA leads to a dramatic increase in MTA2 levels, and tamoxifen-treated breast cancer patients with low Rho GDIa and high MTA2 protein levels appear to exhibit a shorter disease-free survival time compared with all other patients. These are the first data to suggest a clinically important connection between the Rho GDIa and MTA2 pathways. Our data also suggest a possible mechanism, in which the loss of Rho GDIa function promotes distant progression of breast tumors by triggering downstream molecules, such as MTA2, with metastasis-promoting activities. If Rho GDIa works as a suppressor of prometastatic genes, then genes such as MTA2 and ROK would be activated and present as druggable targets for treatment of breast cancer patients with metastatic or tamoxifen-resistant disease. The association of combined Rho GDIa and MTA2 status with clinical outcome supports our hypothesis that Rho GDIa loss can cause resistance to tamoxifen.
There are limitations to this study. First, the hormone-resistant phenotype conferred via Rho GDIa silencing has been shown in only one human breast cancer cell line. For this finding to be generalizable, it will be important to test the effects of Rho GDIa in other ER-positive models. Second, the presented clinical data are based on a retrospective analysis, which may suffer from bias. Future prospective studies could clarify the role of Rho GDIa and MTA2 in breast cancer.
